187 related articles for article (PubMed ID: 15667873)
41. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
White WM; Sadetsky N; Waters WB; Carroll PR; Litwin MS
J Urol; 2008 Dec; 180(6):2409-13; discussion 2414. PubMed ID: 18930270
[TBL] [Abstract][Full Text] [Related]
42. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Lee IH; Sadetsky N; Carroll PR; Sandler HM
J Urol; 2008 Mar; 179(3):1072-6; discussion 1076. PubMed ID: 18206926
[TBL] [Abstract][Full Text] [Related]
43. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
[TBL] [Abstract][Full Text] [Related]
44. Twelve-month self-reported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health Survey (Short Form-36).
Ficarra V; Novara G; Galfano A; Stringari C; Baldassarre R; Cavalleri S; Artibani W
BJU Int; 2006 Feb; 97(2):274-8. PubMed ID: 16430628
[TBL] [Abstract][Full Text] [Related]
45. Confidence in the ability to communicate with physicians among low-income patients with prostate cancer.
Maliski SL; Kwan L; Krupski T; Fink A; Orecklin JR; Litwin MS
Urology; 2004 Aug; 64(2):329-34. PubMed ID: 15302489
[TBL] [Abstract][Full Text] [Related]
46. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
47. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.
Clark JA; Talcott JA
J Clin Oncol; 2006 Sep; 24(27):4457-63. PubMed ID: 16983114
[TBL] [Abstract][Full Text] [Related]
48. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
49. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.
Litwin MS; Lubeck DP; Spitalny GM; Henning JM; Carroll PR
Cancer; 2002 Jul; 95(1):54-60. PubMed ID: 12115317
[TBL] [Abstract][Full Text] [Related]
50. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
51. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
52. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
53. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
D'Ambrosio DJ; Ruth K; Horwitz EM; Chen DY; Pollack A; Buyyounouski MK
Urology; 2008 May; 71(5):938-41. PubMed ID: 18279939
[TBL] [Abstract][Full Text] [Related]
54. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
55. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
56. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
57. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE.
Latini DM; Chan JM; Cowan JE; Arredondo SA; Kane CJ; Penson DF; DuChane J; Carroll PR;
Urology; 2006 Dec; 68(6):1242-7. PubMed ID: 17141841
[TBL] [Abstract][Full Text] [Related]
58. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
59. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
60. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor.
Hu JC; Elkin EP; Krupski TL; Gore J; Litwin MS
Cancer; 2006 Jul; 107(2):281-8. PubMed ID: 16779794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
